Nothing Special   »   [go: up one dir, main page]

UY36112A - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer - Google Patents

Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer

Info

Publication number
UY36112A
UY36112A UY0001036112A UY36112A UY36112A UY 36112 A UY36112 A UY 36112A UY 0001036112 A UY0001036112 A UY 0001036112A UY 36112 A UY36112 A UY 36112A UY 36112 A UY36112 A UY 36112A
Authority
UY
Uruguay
Prior art keywords
compounds
quinolin
ona
treat cancer
salts
Prior art date
Application number
UY0001036112A
Other languages
English (en)
Inventor
Kurt Gordon Pike
Bernard Christophe Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY36112A publication Critical patent/UY36112A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La memoria descriptiva se refiere generalmente a los compuestos de Fórmula (I): y las sales farmacéuticamente aceptables de estos, donde Q, R1, R2, R3, R4 y R5 tienen cualquiera de los significados definidos en la presente. La memoria descriptiva también se refiere al uso de tales compuestos y sales de estos para tratar o prevenir enfermedades mediadas por la cinasa ATM, incluyendo el cáncer. La memoria descriptiva además se refiere a las formas cristalinas de los compuestos de compuestos imidazo[4,5- c]quinolin-2-ona y las sales farmacéuticamente aceptables de estos; las composiciones farmacéuticas que comprenden tales compuestos y sales.
UY0001036112A 2014-05-08 2015-05-06 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer UY36112A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08

Publications (1)

Publication Number Publication Date
UY36112A true UY36112A (es) 2015-10-30

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036112A UY36112A (es) 2014-05-08 2015-05-06 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer

Country Status (38)

Country Link
US (4) US9428503B2 (es)
EP (1) EP3140303B1 (es)
JP (1) JP6505131B2 (es)
KR (1) KR102013021B1 (es)
CN (1) CN106255692B (es)
AP (1) AP2016009532A0 (es)
AR (1) AR100340A1 (es)
AU (1) AU2015257456B2 (es)
CA (1) CA2946459C (es)
CL (1) CL2016002735A1 (es)
CR (1) CR20160523A (es)
CY (1) CY1120248T1 (es)
DK (1) DK3140303T3 (es)
DO (1) DOP2016000281A (es)
EA (1) EA031674B1 (es)
ES (1) ES2670416T3 (es)
HR (1) HRP20180697T1 (es)
HU (1) HUE037558T2 (es)
IL (1) IL248397B (es)
LT (1) LT3140303T (es)
MA (1) MA39960A (es)
MX (1) MX2016014639A (es)
NI (1) NI201600166A (es)
NO (1) NO2714752T3 (es)
NZ (1) NZ726042A (es)
PE (1) PE20170403A1 (es)
PH (1) PH12016502168A1 (es)
PL (1) PL3140303T3 (es)
PT (1) PT3140303T (es)
RS (1) RS57223B1 (es)
SG (1) SG11201609164VA (es)
SI (1) SI3140303T1 (es)
SV (1) SV2016005312A (es)
TN (1) TN2016000458A1 (es)
TR (1) TR201807101T4 (es)
TW (1) TWI662034B (es)
UY (1) UY36112A (es)
WO (1) WO2015170081A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016239270B2 (en) * 2015-04-02 2020-03-26 Merck Patent Gmbh Imidazolonyl quinolines and use thereof as ATM kinase inhibitors
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
AU2017237394A1 (en) * 2016-03-21 2018-11-01 Astrazeneca Ab Cinnolin-4-amine compounds and their use in treating cancer
EA201891866A1 (ru) 2016-04-07 2019-04-30 Астразенека Аб N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
UA123032C2 (uk) 2016-12-20 2021-02-03 Астразенека Аб Амінотриазолопіридинові сполуки та їхнє застосування у лікуванні раку
KR102660196B1 (ko) * 2017-01-09 2024-04-24 임팩트 테라퓨틱스 (상하이), 인코포레이티드 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
CN110312717B (zh) * 2017-02-27 2022-04-12 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN112752758B (zh) * 2018-09-14 2023-05-23 苏州赞荣医药科技有限公司 作为ATM激酶选择性调节剂的咪唑并[4,5-c]噌啉-2-酮化合物及其用途
CA3116234A1 (en) * 2018-10-15 2020-04-23 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
AU2020231045B2 (en) * 2019-03-05 2023-03-16 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
CN114026097B (zh) * 2019-07-10 2024-02-23 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
WO2021047646A1 (en) * 2019-09-12 2021-03-18 Impact Therapeutics, Inc Substituted imidazoquinoxaline compounds and uses thereof
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021146127A1 (en) * 2020-01-13 2021-07-22 Zhanggui Wu Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatment
CN116194109A (zh) 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US20080262021A1 (en) 2003-11-21 2008-10-23 Novartis Ag 1H-Imidazoquinoline Derivatives as Prote In Kinase Inhibitors
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010139747A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AU2010255727B2 (en) 2009-06-04 2013-02-28 Novartis Ag 1H-imidazo[4,5-c]quinolinone derivatives
RU2557658C2 (ru) * 2009-09-28 2015-07-27 Ф.Хоффманн-Ля Рош Аг Бензоксепиновые ингибиторы pi3 и способы применения
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
RU2013113177A (ru) 2010-08-26 2014-10-10 Хитачи Констракшн Машинери Ко., Лтд. Строительная машина
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN103402520A (zh) 2010-12-06 2013-11-20 皮拉马尔企业有限公司 具有取代基的咪唑并喹啉衍生物
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
WO2015170081A1 (en) 2015-11-12
EP3140303A1 (en) 2017-03-15
HUE037558T2 (hu) 2018-09-28
CN106255692A (zh) 2016-12-21
IL248397B (en) 2019-02-28
SG11201609164VA (en) 2016-12-29
SV2016005312A (es) 2017-03-16
US20180134699A1 (en) 2018-05-17
CY1120248T1 (el) 2019-07-10
RS57223B1 (sr) 2018-07-31
EA201692095A1 (ru) 2017-08-31
US20160368920A1 (en) 2016-12-22
KR102013021B1 (ko) 2019-08-21
EA031674B1 (ru) 2019-02-28
PT3140303T (pt) 2018-05-25
MA39960A (fr) 2018-03-28
US20150336952A1 (en) 2015-11-26
US10189834B2 (en) 2019-01-29
CA2946459A1 (en) 2015-11-12
KR20160147054A (ko) 2016-12-21
HRP20180697T1 (hr) 2018-06-01
NZ726042A (en) 2018-08-31
AR100340A1 (es) 2016-09-28
AP2016009532A0 (en) 2016-11-30
LT3140303T (lt) 2018-05-25
PL3140303T3 (pl) 2018-08-31
US20190185468A1 (en) 2019-06-20
PH12016502168B1 (en) 2016-12-19
PH12016502168A1 (en) 2016-12-19
TW201625609A (zh) 2016-07-16
AU2015257456A1 (en) 2016-11-24
JP6505131B2 (ja) 2019-04-24
CA2946459C (en) 2022-07-12
ES2670416T3 (es) 2018-05-30
TWI662034B (zh) 2019-06-11
CR20160523A (es) 2017-04-27
NO2714752T3 (es) 2018-04-21
CN106255692B (zh) 2019-02-26
EP3140303B1 (en) 2018-03-28
US9428503B2 (en) 2016-08-30
DK3140303T3 (en) 2018-06-06
AU2015257456B2 (en) 2018-02-15
CL2016002735A1 (es) 2017-02-10
NI201600166A (es) 2017-03-13
DOP2016000281A (es) 2016-12-15
BR112016025153A8 (pt) 2021-07-20
TR201807101T4 (tr) 2018-06-21
TN2016000458A1 (en) 2018-04-04
JP2017514877A (ja) 2017-06-08
MX2016014639A (es) 2017-03-06
BR112016025153A2 (pt) 2017-08-15
US9822111B2 (en) 2017-11-21
PE20170403A1 (es) 2017-05-07
SI3140303T1 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36285A (es) Compuestos que inhiben la proteína mcl-1
NI201500167A (es) Compuestos químicos
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
DOP2015000170A (es) Compuestos químicos
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
ECSP19066134A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CL2017000223A1 (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2017000827A1 (es) Inhibidores de aldosterona sintasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220620